Advanced Biologics' OsteoAMP® Shows Evidence of Superior Fusion Rates Compared to rhBMP-2
Apr 16, 2012, 08:00 ET
LADERA RANCH, Calif., April 16, 2012 /PRNewswire/ -- Advanced Biologics announced today that they will be presenting data at the American Academy of Neurosurgeons (AANS) meeting this week in Miami, FL showcasing a clinical study demonstrating superior lumbar fusion rates for OsteoAMP® when compared to rhBMP-2 (Infuse®, Medtronic). In a blinded, multi-center clinical and radiological study, fusion analysis showed superiority for OsteoAMP® in producing fusions when compared to rhBMP-2. Fusions (TLIF/LLIF) were assessed by a blinded independent radiologist at various time points (3months, 6months, 12months and 18 months) for both OsteoAMP and rhBMP-2. Analysis showed statistically significant superiority for OsteoAMP at all time points (p<0.02). In addition, the study revealed that patients in the OsteoAMP® arm had 80% fewer complications than in the rhBMP-2 arm. The study has been submitted for peer review.
"These early results are extremely meaningful," stated President, Amit Govil. "They further substantiate OsteoAMP as a viable option for surgeons, hospitals and patients searching for a cost-effective and safer option to rhBMP-2. We are currently enrolling patients in additional clinical trials to further validate our technology."
OsteoAMP® is an award-winning allogeneic growth factor that is a lower-cost alternative to recombinant growth factors, such as rhBMP-2 (Infuse®, Medtronic). Additionally, OsteoAMP®'s four distinctive formats (granules, compressible sponges, putty, and structural grafts) provide a distinct advantage by allowing surgeons to tailor deliver the technology according to their needs in surgery.
About Advanced Biologics
Founded in 2009, Advanced Biologics (ABC) is a privately-held company focused on developing innovative and clinically relevant biologic solutions across a wide degree of medical specialties. The OsteoAMP® family of osteoinductive/conductive products is the first line of orthobiologic offerings produced by ABC. ABC was awarded the Best New Regenerative Technology award in 2009, Best New Biomaterial Technology Award in 2010, and 2011 Best New Technology in Biomaterials and Biologics by the Orthopedics This Week Spine Technology Awards. Other technology platforms to follow include an allograft-derived stem cell product and a shape-memory, anti-bacterial synthetic portfolio. www.advancedbiologics.com
SOURCE Advanced Biologics, LLC
Share this article